RU2003116096A - METHOD FOR TREATING UROGENITAL INFECTIONS - Google Patents

METHOD FOR TREATING UROGENITAL INFECTIONS

Info

Publication number
RU2003116096A
RU2003116096A RU2003116096/14A RU2003116096A RU2003116096A RU 2003116096 A RU2003116096 A RU 2003116096A RU 2003116096/14 A RU2003116096/14 A RU 2003116096/14A RU 2003116096 A RU2003116096 A RU 2003116096A RU 2003116096 A RU2003116096 A RU 2003116096A
Authority
RU
Russia
Prior art keywords
multivalent vaccine
urogenital infections
patient
biologically active
active drug
Prior art date
Application number
RU2003116096/14A
Other languages
Russian (ru)
Other versions
RU2240821C1 (en
Inventor
Виктор Михайлович Бондаренко
Екатерина Алексеевна Курбатова
Надежда Борисовна Егорова
Андрей Евгеньевич Вершинин
Виктор Евсеевич Радзинский
Виктор Георгиевич Митков
Наталья Евгеньевна Климова
Борис Федорович Семенов
Original Assignee
Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова
Filing date
Publication date
Application filed by Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова filed Critical Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова
Priority to RU2003116096/14A priority Critical patent/RU2240821C1/en
Priority claimed from RU2003116096/14A external-priority patent/RU2240821C1/en
Application granted granted Critical
Publication of RU2240821C1 publication Critical patent/RU2240821C1/en
Publication of RU2003116096A publication Critical patent/RU2003116096A/en

Links

Claims (1)

Способ лечения урогенитальных инфекций, включающий введение пациенту биологически-активного препарата, отличающийся тем, что в качестве биологически-активного препарата используют поливалентную вакцину из антигенов, выделенных из штаммов Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli и Staphylococcus aureus, вводят ее подкожно 5-ти кратно с суммарной дозой 0,9 мг, первую инъекцию поливалентной вакцины осуществляют в дозе 0,1 мг, последующие четыре инъекции - по 0,2 мг с интервалом между ними 3-5 суток, при этом курс введения пациенту поливалентной вакцины чередуют с курсом лечения антибиотиками.A method for the treatment of urogenital infections, comprising administering to the patient a biologically active drug, characterized in that a multivalent vaccine is used as a biologically active drug from antigens isolated from Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli and Staphylococcus aureus strains, 5 subcutaneously administered multiple times with a total dose of 0.9 mg, the first injection of a multivalent vaccine is carried out at a dose of 0.1 mg, the next four injections are 0.2 mg each with an interval of 3-5 days between them, while the course of administration of the multivalent vaccine to the patient is alternated with rsom antibiotic treatment.
RU2003116096/14A 2003-06-02 2003-06-02 Method for treating urogenital infections RU2240821C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2003116096/14A RU2240821C1 (en) 2003-06-02 2003-06-02 Method for treating urogenital infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2003116096/14A RU2240821C1 (en) 2003-06-02 2003-06-02 Method for treating urogenital infections

Publications (2)

Publication Number Publication Date
RU2240821C1 RU2240821C1 (en) 2004-11-27
RU2003116096A true RU2003116096A (en) 2004-12-27

Family

ID=34310924

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003116096/14A RU2240821C1 (en) 2003-06-02 2003-06-02 Method for treating urogenital infections

Country Status (1)

Country Link
RU (1) RU2240821C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2933065C (en) * 2013-12-12 2021-08-24 Innovation Technologies, Inc. Materials and methods for controlling infections

Similar Documents

Publication Publication Date Title
Bowdre et al. Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline.
Projan Preclinical pharmacology of GAR‐936, a novel glycylcycline antibacterial agent
RU2010140682A (en) METHOD FOR TREATING PATIENTS FROM INFECTION, PHARMACEUTICAL COMPOSITION (OPTIONS) AND MEDICINE
JP2005520778A5 (en)
JP2006514092A5 (en)
Campoli-Richards et al. Netilmicin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use
JPH1053533A (en) Treatment of sepsis and ards
Mordenti et al. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model
GRAY The choice of antibiotic for treating infective endocarditis
RU2003116096A (en) METHOD FOR TREATING UROGENITAL INFECTIONS
CN105853449B (en) A kind of antibacterial compound drug of amikacin sulfate for injection
Egert et al. Comparison of methicillin, nafcillin, and oxacillin in therapy of Staphylococcus aureus endocarditis in rabbits
SK284791B6 (en) Use of 8a-azalides in the treatment or prevention of bacterial respiratory and enteric infections in livestock animals
Nicolau et al. Choosing between the new cephalosporin antibiotics: a pharmacodynamic approach
EP0238207B1 (en) Bactericidal mixtures
Sande Antimicrobial therapy for two serious bacterial infections: enterococcal endocarditis and nosocomial pneumonia
US3629451A (en) Method of treating bacterial infections
Ziv et al. Elevation and prolongation of serum ampicillin and amoxycillin concentrations in calves by the concomitant administration of probenecid
Blake et al. Clinical observations on terramycin
Frost et al. Antibacterial activity of heneicomycin
Papich Drug therapy and selection in exotic medicine.
Lam et al. SDZ MRL 953, a novel synthetic lipid A analogue, induces tolerance to the lethal effects of endotoxin and enhances nonspecific immunity
CN112057606A (en) Use of FGF19 in a medicament for the treatment and/or prevention of sepsis-induced organ damage
Hughes Antibiotic treatment of chronic bronchitis
Cheadle et al. Effects of muramyl dipeptide and clindamycin in a murine abdominal abscess model